.
  • NIFTY 25,683.30 -193.55 (-0.75%)
  • SENSEX 83,576.24 -604.72 (-0.72%)
 
BSE
NSE

Friday, January 09, 2026 , BSE Sensex : 83,576.24 83,576.24(-0.72%) , Adani Ports : 1,435.75 1,435.75(-1.98%) , Asian Paints : 2,824.50 2,824.50(1.36%) , Axis Bank : 1,271.95 1,271.95(-1.16%) , Bajaj Finance : 960.55 960.55(-1.16%) , Bajaj Finserv : 1,992.70 1,992.70(-0.80%) , Bharat Electron : 418.85 418.85(0.77%) , Bharti Airtel : 2,027.30 2,027.30(-1.89%) , Eternal : 284.40 284.40(0.32%) , HCL Technologies : 1,662.30 1,662.30(0.86%) , HDFC Bank : 938.70 938.70(-0.83%) , Hind. Unilever : 2,373.75 2,373.75(-0.53%) , ICICI Bank : 1,403.55 1,403.55(-2.22%) , Infosys : 1,614.75 1,614.75(0.10%) , Interglobe Aviat : 4,844.70 4,844.70(-1.22%) , ITC : 337.10 337.10(-1.11%) , Kotak Mah. Bank : 2,126.75 2,126.75(-0.29%) , Larsen & Toubro : 4,026.75 4,026.75(-0.03%) , M & M : 3,677.05 3,677.05(-1.26%) , Maruti Suzuki : 16,501.00 16,501.00(-0.98%) , NTPC : 336.05 336.05(-2.34%) , Power Grid Corpn : 258.55 258.55(-0.37%) , Reliance Industr : 1,475.30 1,475.30(0.34%) , SBI : 1,000.00 1,000.00(0.22%) , Sun Pharma.Inds. : 1,729.95 1,729.95(-1.79%) , Tata Steel : 178.30 178.30(-1.05%) , TCS : 3,208.00 3,208.00(0.12%) , Tech Mahindra : 1,581.20 1,581.20(0.23%) , Titan Company : 4,203.00 4,203.00(-1.04%) , Trent : 3,975.80 3,975.80(-0.32%) , UltraTech Cem. : 11,951.85 11,951.85(-0.89%) ,

Nifty 50 : 25,683.30 -193.55(-0.75%) , Adani Enterp. : 2,153.70 -60.30(-2.72%) , Adani Ports : 1,435.90 -29.30(-2.00%) , Apollo Hospitals : 7,256.50 -108.00(-1.47%) , Asian Paints : 2,825.50 39.00(1.40%) , Axis Bank : 1,272.00 -14.80(-1.15%) , Bajaj Auto : 9,562.50 -198.00(-2.03%) , Bajaj Finance : 959.60 -12.35(-1.27%) , Bajaj Finserv : 1,992.40 -16.50(-0.82%) , Bharat Electron : 418.65 3.00(0.72%) , Bharti Airtel : 2,027.10 -39.20(-1.90%) , Cipla : 1,465.70 5.10(0.35%) , Coal India : 418.35 -6.90(-1.62%) , Dr Reddy's Labs : 1,210.10 3.20(0.27%) , Eicher Motors : 7,507.00 -44.00(-0.58%) , Eternal : 284.35 0.80(0.28%) , Grasim Inds : 2,776.90 -15.10(-0.54%) , HCL Technologies : 1,661.40 14.70(0.89%) , HDFC Bank : 939.00 -7.70(-0.81%) , HDFC Life Insur. : 749.90 -8.25(-1.09%) , Hind. Unilever : 2,372.60 -14.10(-0.59%) , Hindalco Inds. : 900.95 -3.00(-0.33%) , ICICI Bank : 1,404.30 -30.70(-2.14%) , Infosys : 1,614.10 0.80(0.05%) , Interglobe Aviat : 4,844.00 -62.50(-1.27%) , ITC : 337.15 -3.75(-1.10%) , Jio Financial : 287.25 -6.30(-2.15%) , JSW Steel : 1,158.80 2.90(0.25%) , Kotak Mah. Bank : 2,126.80 -6.20(-0.29%) , Larsen & Toubro : 4,025.20 -3.20(-0.08%) , M & M : 3,677.30 -46.70(-1.25%) , Maruti Suzuki : 16,501.00 -163.00(-0.98%) , Max Healthcare : 1,017.20 -12.60(-1.22%) , Nestle India : 1,299.10 -7.80(-0.60%) , NTPC : 336.00 -8.40(-2.44%) , O N G C : 234.09 2.67(1.15%) , Power Grid Corpn : 258.00 -1.30(-0.50%) , Reliance Industr : 1,475.30 4.70(0.32%) , SBI : 1,000.50 2.50(0.25%) , SBI Life Insuran : 2,070.00 -12.90(-0.62%) , Shriram Finance : 975.40 -17.50(-1.76%) , Sun Pharma.Inds. : 1,729.90 -30.80(-1.75%) , Tata Consumer : 1,175.90 -21.50(-1.80%) , Tata Motors PVeh : 354.15 -5.30(-1.47%) , Tata Steel : 178.40 -1.72(-0.95%) , TCS : 3,207.80 3.90(0.12%) , Tech Mahindra : 1,582.20 4.30(0.27%) , Titan Company : 4,201.80 -47.20(-1.11%) , Trent : 3,972.90 -17.50(-0.44%) , UltraTech Cem. : 11,937.00 -127.00(-1.05%) , Wipro : 261.95 -0.25(-0.10%) , Friday, January 09, 2026

Home >> Markets >> Equities >> News - News Details
DAILY MARKET TRACKER
MARKET ANALYSIS
NEWS
CORPORATE INFO
CORPORATE ACTIONS
OTHER MARKETS
Hot Pursuit
30-Dec-2025     11:21
Lupin signs exclusive licensing deal with Gan & Lee for novel GLP-1 receptor agonist
According to an exchange filing, the agreement strengthens Lupin's diabetes portfolio and expands its presence in the obesity segment. Bofanglutide, developed by Gan & Lee, is intended for adults with type 2 diabetes and for weight management in overweight or obese individuals. As a potential first-in-class fortnightly GLP-1 agonist, clinical data indicate that Bofanglutide delivers weight loss results comparable to or better than existing GLP-1 alternatives, with the added convenience of once-every-two-weeks dosing compared to weekly injections, while maintaining safety and tolerability consistent with the GLP-1 class. The drug also helps reduce blood glucose levels and body weight.

The company said obesity is emerging as a major health concern in India, with an estimated 174 million adults overweight and around 50 million classified as obese. Diabetes affects approximately 90 million adults in the country. Under the terms of the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India.

Nilesh Gupta, Managing Director, Lupin, said, 'We are committed to offering the best solutions for managing chronic metabolic diseases like diabetes, and addressing obesity is one of the most urgent global health challenges. This partnership demonstrates our strategic focus on the GLP-1 class of drugs and highlights our dedication to delivering high-quality, innovative therapies for our patients.'

Rajeev Sibal, President of India Region Formulations at Lupin, said, 'Bofanglutide offers a significant advantage with its convenient fortnightly dosing, thus reducing the number of injections by 50% while delivering outcomes and clinically proven efficacy that matches or surpasses existing weekly formulations. This strategic alliance marks a pivotal step in strengthening Lupin's leadership in metabolic health, expanding our innovative portfolio, and reaffirming our commitment to delivering transformative solutions.'

Gan & Lee Executive Vice President & Chief Commercial Officer (EVP & CCO) Kai Du and Key Accounts Director, Dr Dhaval Soneji commented and believed, 'On the heels of the Latin American exclusive agreement signed in November, this new partnership with Lupin for the Indian market further underscores Gan & Lee's rapid global strategic advancement. Our goal is to provide superior treatment options for patients with metabolic diseases worldwide, while showcasing the value of Chinese biopharmaceutical innovation on the global stage.'

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025.

The counter rose 0.11% to currently trade at Rs 2,081.80 on the BSE.

Powered by Capital Market - Live News